Clinical Edge Journal Scan

DBT lowers risk for advanced BC diagnosis in women with dense breasts and at high risk


 

Key clinical point: Digital breast tomosynthesis (DBT) reduced the likelihood of advanced breast cancer (BC) diagnosis compared with digital mammography in women with extremely dense breasts and a high risk for BC.

Major finding: Overall screening outcomes per 1000 examinations were similar with DBT vs digital mammography for interval invasive cancer (difference −0.04; 95% CI −0.14 to 0.06); however, the advanced cancer detection rate was lower in women with extremely dense breasts and a high BC risk (difference −0.53; 95% CI −0.97 to −0.10).

Study details: Findings are from a cohort study including 504,427 women with no history of BC or mastectomy who underwent 1,003,900 digital mammography screening examinations or 374,002 DBT screening examinations.

Disclosures: This study was funded by Patient-Centered Outcomes Research Institute, National Cancer Institute, and other sources. Some authors declared receiving grants, consulting fees, or royalties from or serving as consultants or on the editorial board for several sources.

Source: Kerlikowske K et al. Association of screening with digital breast tomosynthesis vs digital mammography with risk of interval invasive and advanced breast cancer. JAMA. 2022;327(22):2220–2230 (Jun 14). Doi: 10.1001/jama.2022.7672

Recommended Reading

Highlights in Early Breast Cancer From the 2022 American Society of Clinical Oncology Annual Meeting
Breast Cancer ICYMI
Cancer may increase risk of type 2 diabetes
Breast Cancer ICYMI
Commentary: Treating ER+ Breast Cancer and Brain Metastases, July 2022
Breast Cancer ICYMI
Quality of life benefit exaggerated in some cancer studies
Breast Cancer ICYMI
Sociogenomics may explain race disparities in breast cancer mortality
Breast Cancer ICYMI
Study confirms BRCA1 and BRCA2 linked to seven cancers
Breast Cancer ICYMI
Select patients with breast cancer may skip RT after lumpectomy
Breast Cancer ICYMI
Amazon involved with new cancer vaccine clinical trial
Breast Cancer ICYMI
Hormone therapy didn’t increase recurrence or mortality in women treated for breast cancer
Breast Cancer ICYMI
HER2-low metastatic BC: Phase 3 establishes trastuzumab deruxtecan as a new standard-of-care
Breast Cancer ICYMI